Across TCGA pan-cancer cohorts, NAP1L1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated NAP1L1 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NAP1L1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NAP1L1 expression acts as an unfavorable survival marker.
BLCA, UCEC, and HNSC are the cancer types where NAP1L1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.